ADT Not Linked to Dementia in Nonmetastatic Prostate Cancer

No increased risk of dementia for androgen deprivation therapy use versus nonuse.
No increased risk of dementia for androgen deprivation therapy use versus nonuse.

(HealthDay News) -- For men with prostate cancer, use of androgen deprivation therapy (ADT) seems not to be associated with dementia, according to a study published online in the Journal of Clinical Oncology.

Farzin Khosrow-Khavar, PhD, from McGill University in Hamilton, Canada, and colleagues examined whether use of ADT is associated with increased risk of dementia, including Alzheimer's disease. A cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer from April 1, 1988, to April 30, 2015 were recruited and followed until April 30, 2016. To account for delays associated with dementia diagnosis and minimize reverse causality, ADT exposure was lagged by 1 year.

The researchers found that 799 patients were newly diagnosed with dementia during a mean follow-up of 4.3 years (incidence, 6.0 per 1,000 person-years). ADT use was not associated with increased risk of dementia compared with nonuse (incidence, 7.4 versus 4.4 per 1,000 person-years; adjusted hazard ratio, 1.02; 95 percent confidence interval, 0.87 to 1.19). Cumulative duration of use and no single type of ADT correlated with increased risk of dementia in secondary analyses.

"In this population-based study, the use of ADT was not associated with an increased risk of dementia," the authors write. "Additional studies in different settings are needed to confirm these findings."

Reference

1. Khosrow-Khavar F, Rej S, Yin H, Aprikian A, and Azoulay L. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. J Clin Onc. doi: 10.1200/JCO.2016.69.6203.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters